You are here: Home > Investor Relations

 Investor Relations

 
 Recent Releases

 Archived Releases

 Annual Meeting

 Analyst Coverage

 Corporate Governance

 SEC Filings

 XBRL Interactive Data
 Files


 Transfer Agent

 Auditors

 E-Mail Alerts
 
 Contact Us

4/22/2014 ELITE PHARMACEUTICALS GRANTED NEW PATENT FOR ABUSE DETERRENT TECHNOLOGY

4/14/2014 Elite Pharmaceuticals Secures Funding Commitment Of Up To $40 Million From Lincoln Park Capital, LLC

3/27/2014 Elite Pharmaceuticals Appoints Barbara Ellison as Vice President of Quality Operations and Regulatory Affairs
- New Hire Brings Track Record of Success -


3/24/2014 Elite Pharmaceuticals Announces Supplemental Application for Site Transfer of Isradipine

3/10/2014 Elite Pharmaceuticals Expands Abuse Deterrent Technology Patent Portfolio Internationally

More Releases...

Click Here for a complete archive


Elite Pharmaceuticals, Inc. 165 Ludlow Ave., Northvale, NJ 07647    Phone:  201-750-2646  Fax:  201-750-2755 
E Mail:  webmaster@elitepharma.com